Clinical Trials for Cervical Cancer

An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable metastatic melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma harboring selected MAPK-pathway mutations, ECOG 0–1, and no suitable standard therapy receive oral IPN01194 monotherapy. IPN01194 inhibits ERK1/2, downstream components of MAPK signaling.

ClinicalTrials.gov ID: NCT06305247

A Phase I Dose-Escalation Trial of vvDD-hIL2-2-RG-1 (Vaccina Virus Double Deleted) Administered by Intra-tumoral (IT) Injection for Metastatic Gastrointestinal and Peritoneal Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults under 70 with metastatic gastrointestinal cancer that has progressed after standard chemotherapy, or who are ineligible for it, and an injectable tumor receive a single intratumoral injection of vvDD-hIL-2-RG-1. This oncolytic vaccinia virus is engineered for tumor-selective activity and expression of membrane-bound human IL-2 to stimulate antitumor T-cell responses.

ClinicalTrials.gov ID: NCT07001592

A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable HER2‑negative adenocarcinoma of the esophagus/GEJ/stomach (no prior metastatic therapy; ECOG 0–2) receive an alternating doublet sFOLFOXIRI schedule: mFOLFOX6 on odd cycles and FOLFIRI on even cycles every 2 weeks. Optional nivolumab (PD‑1 inhibitor) may be added per label to enhance antitumor activity.

ClinicalTrials.gov ID: NCT05332002

Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally recurrent ovarian, fallopian tube, primary peritoneal, endometrial, cervical, or vaginal cancers confined to the abdomen/pelvis receive daily oral talazoparib, a PARP1/2 inhibitor and potent PARP trapper/radiosensitizer, starting before and during fractionated external-beam radiation. Eligible patients must have ECOG 0–1 (or adequate life expectancy), adequate organ function, and at least one non-previously-irradiated measurable lesion; prior RT to the planned field, carcinomatosis/ascites/hepatic metastases, or need for extended-field RT are excluded.

ClinicalTrials.gov ID: NCT03968406

A Phase 1, Open-label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of an Anti-LILRB2 / PD-L1 Bispecific Antibody SPX- 303 in Patients With Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors that have progressed after prior therapy and lack suitable treatment options receive intravenous SPX-303 every 3 weeks in dose-escalation and expansion cohorts. SPX-303 is an investigational bispecific antibody targeting LILRB2 on myeloid cells and PD-L1 to counter tumor-associated immune suppression.

ClinicalTrials.gov ID: NCT06259552

A Phase Ib Open Label Randomised Clinical Trial to Evaluate Safety and Efficacy of BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Compared With Pembrolizumab Monotherapy for the First-line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable recurrent or metastatic head and neck squamous cell carcinoma who have not received systemic therapy for recurrent or metastatic disease and are candidates for pembrolizumab monotherapy are randomized to pembrolizumab alone or with BI 770371, with or without cetuximab. BI 770371 blocks the SIRPα–CD47 interaction to promote immune-cell engulfment of tumor cells; cetuximab inhibits EGFR signaling.

ClinicalTrials.gov ID: NCT06806852

Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic NSCLC, head and neck squamous cell carcinoma, or melanoma may be eligible if they are checkpoint inhibitor–naive or have progressed after anti-PD-(L)1 therapy; additional PD-L1 criteria apply to checkpoint inhibitor–naive NSCLC and head and neck cancer. Treatment combines pembrolizumab with oral CJRB-101, an investigational live biotherapeutic containing Leuconostoc mesenteroides that aims to modulate gut microbiome–associated antitumor immunity.

ClinicalTrials.gov ID: NCT05877430

Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent/metastatic, incurable HNSCC (oral cavity, oropharynx, hypopharynx, larynx, or cervical node with occult primary) who are chemo‑naïve in the R/M setting and not candidates for infusional 5‑FU receive pembrolizumab (anti–PD‑1) plus weekly carboplatin/paclitaxel for six cycles, then pembrolizumab maintenance. Key exclusions include untreated symptomatic CNS mets, active autoimmune disease needing immunosuppression, prior severe hypersensitivity to carboplatin/paclitaxel, and significant uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT04858269

A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic bladder cancer or squamous cell carcinoma of the lung, esophagus, skin, or anogenital region, generally after standard therapy, receive EVOLVE104 monotherapy. This investigational trispecific T-cell engager binds tumor-cell ULBP2/5/6 and T-cell CD3 and CD2 to promote T-cell killing with CD2 costimulation.

ClinicalTrials.gov ID: NCT07217171

A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with incurable locally advanced, recurrent, or metastatic solid tumors who lack appropriate standard treatment receive once-daily oral CP-383, an investigational dual DHODH/TEAD4 inhibitor. Dose expansion focuses on selected cancers, including colorectal, small-cell lung, and head and neck cancers, with some cohorts defined by tumor alterations.

ClinicalTrials.gov ID: NCT07030257